ADH 1

Drug Profile

ADH 1

Alternative Names: ADH-1; ADH-100001; Exherin

Latest Information Update: 23 Feb 2011

Price : $50

At a glance

  • Originator McGill University
  • Developer Adherex Technologies
  • Class Antineoplastics; Cyclic peptides; Oligopeptides
  • Mechanism of Action Angiogenesis inhibitors; Cadherin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Malignant melanoma; Solid tumours

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 22 Apr 2009 Preclinical drug interactions data presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009)
  • 02 Jun 2008 Interim efficacy data from a phase I trial in Malignant melanoma released by Adherex Technologies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top